

Healthy Volunteers

**A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants**

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT02882009 WP39322

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

The purpose of this randomized, open-label, parallel-group, placebo-controlled study is to assess pain following subcutaneous (SC) administration of gantenerumab as a high-concentration liquid formulation (HCLF) at different injection speeds. The total duration of the study for each healthy participant will be up to approximately 21 weeks.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT02882009 WP39322**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥ 40 Years & ≤ 80 Years

**Healthy Volunteers**  
Accepts Healthy Volunteers

---